Multiple Sclerosis GP update Martin Duddy Consultant Neurologist Royal Victoria Infirmary Newcastle upon Tyne.

Slides:



Advertisements
Similar presentations
OBJECTIVES: 1.To become empowered and educated to gain control over a disease where you feel no control. 2.To identify the basic outcome measure that you.
Advertisements

Managing an Alemtuzumab Service
Study Design 121 Relapsing-remitting MS patients randomized to –Stress Management Therapy MS active treatment* 16 individual sessions conducted over 24.
Dimethyl Fumarate and Peginterferon b-1a: New Insights Into the Pivotal Trials Pavan Bhargava, MD Johns Hopkins University School of Medicine, Baltimore,
A lady with vomiting. A 23-year-old female student presents to her GP 5 days after returning from a ski holiday. She developed what she thought was a.
Stroke Mark Sudlow Consultant and Senior Lecturer
UK clinical perspective on treatment reviews of multiple sclerosis therapies Alasdair Coles Neurologist, Cambridge, UK.
What Is Meant by "Real-World Data?"
Long-term Safety and Effectiveness of Natalizumab STRATA MS Study.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2013.
Efficacy of fidaxomicin vs vancomycin for C. difficile-associated diarrhoea (CDAD) in pts with cancer Post-hoc analysis of 2 multi-centre, double-blind.
Botulinum toxin type A for the prevention of headaches in adults with chronic migraine.
Overview of Multiple Sclerosis  Valerie Robinson, D.O. 
Rituximab (RITUXAN) & Multiple Sclerosis
Original Article B-Cell Depletion with Rituximab in Relapsing- Remitting Multiple Sclerosis Stephen L. Hauser, M.D., Emmanuelle Waubant, M.D., Ph.D., Douglas.
FREEDOMS II TRIAL.
Are Benzodiazepines Still the Medication of Choice for Patients With Panic Disorder With or Without Agoraphobia? By : s.bruce, PhD et al (Am J Psychiatry.
Fingolimod Therapy for Multiple Sclerosis
Multiple Sclerosis Abdulelah Nuqali Intern. DemyelinationCNSAquired Multiple Sclerosis Optic neuritis Acute Disseminated Encephalomyelitis Hereditary.
Prof.Hanan Habib. To eradicate the offending organisms from the urinary bladder and tissues. The main treatment of UTI is by antibiotics.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 23 Drugs for Multiple Sclerosis.
By Matthew Sampson. Overview What is it? Previous Treatments Monoclonal Antibodies Chimeric Molecules Oral Therapies Hematopoietic Stem Cells Future.
Emerging Therapies for Multiple Sclerosis
Multiple Sclerosis: Clinical Treatment and Current Research Walter Royal, III, MD Associate Professor of Neurology Maryland Center for Multiple Sclerosis.
Arani Nitkunan MA (Cantab), MRCP (UK)(Neurology), PhD February 12th 2015 First Fit Pathway & Multiple Sclerosis.
Multiple Sclerosis (Definition)  “Multiple Sclerosis is a progressive demyelination of neurons in the central nervous system (the Brain and the Spinal.
© 2014 Direct One Communications, Inc. All rights reserved. 1 Controversies in the Treatment of Multiple Sclerosis Sara S. Qureshi, MD The University of.
39-year-old woman with ‘monthly’ headaches Presented by: Anne MacGregor Barts Sexual Health Centre, St. Bartholomew’s Hospital, London, UK CLINICAL CASE.
An Analysis of Monthly Surveillance 3T MRI in MS patients switched from long term natalizumab to teriflunomide in a controlled, prospective study K. Edwards,
Pediatric Neurology Use of Biologic and Chemotherapeutic Agents Pediatric Neurology Use of Biologic and Chemotherapeutic Agents.
Assessment, Targets, Thresholds and Treatment Bryan Williams NICE clinical guideline 127.
The evolving landscape of MS
Disease modifying drugs in MS Eva Havrdová Charles University, First Medical Faculty, Dpt. of Neurology Praha, Czech Republic.
© 2014 Direct One Communications, Inc. All rights reserved. 1 A New Era of Therapy in Multiple Sclerosis: Balancing the Options and Challenges Ahead Jennifer.
Arch Neurol. 2009;66(8): Published online June 8, 2009 (doi: /archneurol ).
Treatment of urinary tract infections Prof. Hanan Habib.
Emerging MS Therapies. Limitations of Current Therapies All are only partially effective All are injectable or IV and have side effects Risks vs benefits.
© 2014 Direct One Communications, Inc. All rights reserved. 1 Natalizumab and Dimethyl Fumarate: A Fresh Take on Pivotal Trials and Reports from Ongoing.
Int J MS Care 7: , 2005/2006. Jan 9 & 10, Clinical Stabilization of a MS Patient after Tonsillectomy presented by Michael C. Levin, MD Department.
Human Physiology Multiple Scolerosis. Multiple sclerosis is an autoimmune disease that affects the brain and spinal cord (central nervous system) autoimmune.
Updates on Optic Neuritis Briar Sexton Neuro-ophthalmology Clinical Day Friday, November 18, 2005.
Journal Insights Into: Oral Therapy for MS-Related Walking Impairment Supplemental Slides.
EXEMPLAR OF MULTIPLE SCLEROSIS INTRODUCTION AND ASSESSMENT.
Treatment of urinary tract infections
Multiple Sclerosis GP update Martin Duddy Consultant Neurologist Royal Victoria Infirmary Newcastle upon Tyne.
CasePerspectives: Illuminating Dark Pathways in Complex MS Cases Program Highlights Stephen Krieger, MD Associate Professor of Neurology Corinne Goldsmith.
Advisory Committee for Peripheral and Central Nervous System Drugs March 7, 2006 Question 1: 1.Has Biogen demonstrated natalizumab’s efficacy on reduced.
GP LABORATORY MEDICINE UPDATE MEETING Investigation of lymphopaenia and neutropenia in Primary Care Huw Roddie.
Tecfidera ® Use in Multiple Sclerosis: A Patient Case Stefanie L. Drahuschak PharmD Candidate Class of 2014 University of Pittsburgh School of Pharmacy.
Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (review of technology appraisal guidance 57) Last modified January 2015.
Laquinimod, an Oral Product in Development for the Treatment of Relapsing Remitting Multiple Sclerosis Steve Glenski, PharmD Medical Affairs Teva Neuroscience.
Carrie M. Hersh, D.O., Robert Fox, M.D.
Four Known Types of MS Clinically isolated syndrome (CIS)
Management of Urinary Tract Infections Renal Block
Management of Urinary Tract Infections Renal Block
Multiple Scleroris Lyle Wiemerslage, PhD.
CONCLUSION-DISCUSSION
Tumefactive rebound of Multiple Sclerosis following cessation of Fingolimod   Sharfaraz Salam, Daniel Dunbar, Tim Lavin, Adrian Pace, Tatiana Mihalova.
Treatment of Multiple Sclerosis
Program Goals Teriflunomide: Pooled Safety Data.
What’s the Big Deal About Brain Atrophy and Neurodegeneration in RRMS?
Oral vs IV High-Dose Methylprednisolone Are Equally Effective in MS
Discussion and Concluding Remarks
Dr Anthony Fok Neurologist and Neuro-ophthalmologist
1 Verstovsek S et al. Proc ASH 2012;Abstract Cervantes F et al.
Oral Therapies in MS.
Treatment of Multiple Sclerosis: Old & New
MS Relapse Management: Team Approaches Colleen Harris MN NP MSCN
CASE STUDIES.
Algorithm based on the 2015 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) recommendations for the management of polymyalgia.
Presentation transcript:

Multiple Sclerosis GP update Martin Duddy Consultant Neurologist Royal Victoria Infirmary Newcastle upon Tyne

epidemiology and nomenclature

risk factors for MS smoking (HR 1.48) –duration and intensity –also risk factor for progression vitamin D status –>100nmol/L HR 0.5 vs <75nmol/L EBV –100% MS seropositivity vs 95% controls –IM HR 2.17

normal clinically isolated syndrome radiologically isolated syndrome McDonald criteria 2005 McDonald criteria 2010 secondary progressive MS clinically definite MS active RRMS shifting the definition

diagnostic criteria (McDonald 2010) Polman et al. Ann Neurol 2011;69:292–302

PPMS

relapsing/ remitting patterns of MS (1996) primary progressive (benign) secondary progressive 85%13% 5% 2% PRMS

Lublin et al. Neurology 2014;83:278 defining phenotypes “The Group recommended at least annual assessment of disease activity by clinical and brain imaging criteria for relapsing MS”

referral for diagnosis

progression of MS

treating MS

treatment of acute relapse disease modification –disease modifying treatments (DMTs) management of symptoms and disability

treatment of acute relapse disease modification –disease modifying treatments (DMTs) management of symptoms and disability

case a 34-year-old woman with MS 2d history of worsening intense pain in a band, right side, roughly T7 distribution. generally fatigued and her right leg feels heavier worsening hesitancy feels similar to a previous relapse successfully treated with oral steroids in primary care on oral fingolimod for 6 months fully ambulant with no new signs on examination

would you? 1.prescribe oral steroids 2.prescribe oral steroids only after checking for a UTI 3.acknowledge episode as relapse but withhold treatment awaiting natural history 4.ask her to contact her MS team if symptoms don’t settle 5.refer as emergency to MS team

management of acute relapse increasingly rare: usually in consultation with local MS team methylprednisolone –oral 500mg x 5d (PPI cover if symptomatic) –IV 1000mg x 3d always specialist centre if on natalizumab, fingolimod or alemtuzumab

treatment of acute relapse disease modification –disease modifying treatments (DMTs) management of symptoms and disability

where are we leaving? NI population study , n=281 –fully independent for all ADLs 29% –unable to manage flight of stairs 23% –in full time employment 25% –institutionalised 5% –unable to use public transport or drive a car33% half leave work force within 3 years of diagnosis 2 employment at 10yr 25% 1.McDonnell & Hawkins Mult Scler 2001;7: Doogan & Playford. Mult Scler 2014;14:646

RRMS interferon-  (Betaferon/Extavia Avonex Rebif) glatiramer acetate (Copaxone) natalizumab (Tysabri) fingolimod (Gilenya) teriflunomide (Aubagio) dimethyl fumarate (BG12, Tecfidera) alemtuzumab (Campath, Lemtrada) pegylated interferon (Plegridy)

how good are current treatments?

reducing relapses transient disability can leave persistent disability –(> 1point EDSS in >15%) impact on patients –work –finances marker of disease activity predictor of later disability

drugreduction in annualised relapse rate against placebo ARR on drug in RCT interferon-  / glatiramer acetate 1 sc im 30-35% pegylated IFN 9 sc Q2W 36%0.29 teriflunomide 2 po33.7%0.35 dimethyl fumarate 3 po49%0.19 fingolimod 4,5 po48-54% natalizumab 6 iv68% (81% active disease)0.26 alemtuzumab 7,8 iv 49% (vs interferon-  ) 0.26 reducing relapse rates 1.Galetta et al. Arch Intern Med 2002;19: Kappos et al. P618 ECTRIMS Fox et al. P AAN Kappos et al. N Engl J Med 2010;362:387 5.Calabresi et al. Lancet Neurol 2014;13:545 6.Polman et al. N Engl J Med 2006;354: Coles et al. Lancet 2012;380: Cohen et al. Lancet 2012;380: Kieseier et al. Mult Scler 2014 Nov 28. pii:

drugreduction in sustained progression in disability rate of progression in placebo interferon-  / glatiramer acetate sc im 12-37%c.30% pegylated interferon sc Q2W 38% (1 yr)10.5% (1 yr) teriflunomidepo30.5%24% dimethyl fumarate po29% (combined analysis: NS CONFIRM)15% finglimodpo37% (F1) NS (F2)19% (F1) natalizumabiv54% (-64% active disease)28% alemtuzumabivNS (CARE-MS 1) -42% (CARE MS2) 20% (IFN-  ) reducing short term disability Calabresi et al. Lancet Neurol 2014;13:657 refs as slide 18 unless stated

reducing MRI measures of inflammation drugreduction in number of new/enlarging T2 lesions reduction in number of Gd+ve lesions interferon-  / glatiramer acetate sc im -78%- pegylated interferon sc Q2W -67%-86% teriflunomidepo -69.4% (T2 and Gd combined) dimethyl fumarate po-78%-82% finglimodpo-74% (F1)-70% (F1) natalizumabiv-83%-84% (active disease) alemtuzumabiv-32% (no. pts vs IFN C-MS2) -60% (no. pts vs IFN C-MS2) Arnold et al BMC Neurol 2014; doi: /s x refs as slide 18 unless stated

TherapyReduction in PBVC IFN β/glatiramer acetate Avonex: positive effect Year 2 pegylated interferonnot presented teriflunomidenot significant dimethyl fumarateno peer reviewed data presented fingolimod–35% (FREEDOMS); –33% (FREEDOMS II); –32% (TRANSFORMS) natalizumab-55% yr 2 alemtuzumab–42% (naive vs. IFN); –24% (previously treated vs. IFN) reducing brain atrophy refs as slide 18 unless stated

NEDA 3 relapses EDSS progression MRI activity NEDA 4 relapses EDSS progression MRI activity brain volume loss definable? achievable? useful?

quoted rates for NEDA3 23% OR 2.56 vs placebo combined analysis logistic regression placebo teriflunomide 23% x 1.6 vs placebo TEMSO crude placebo natalizumab 27% x 13.5 vs placebo AFFIRM RES subgroup Rebif alemtuzumab 39% x 1.75 vs Rebif CARE-MS1 all 2year Havrdova et al Lancet Neurol 2009;8:254 Hardova et al P521 ECTRIMS 2013Freedman et al. Neurology PD5.007 AAN 2012 Giovannoni et al ENS

quoted rates for NEDA3 39.8% 1 year OR 3.06 vs placebo placebo fingolimod 24% OR 4.0 vs placebo combined analysis logistic model Arnold et al BMC Neurol 2014; doi: /s x Bergvall et al P112 ECTRIMS Boston 2014 placebo pegylated interferon

NEDA 4 Freedoms 1 and 2 1. relapse protocol defined 2. EDSS confirmed at 3 months 1.5 from 0; 0.5 over 5; otherwise 1 3. MR: NET2 only: m6, 12, 24 (Gd did not add anything) 4. atrophy: >0.4% Kappos 2014 platform ECTRIMS Boston placebofingolimod OR 4.41 p<0.0001

tolerability and safety interferons (injectables) fingolimod (tablet) natalizumab (infusion) teriflunomide (tablet) DMF (tablet) alemtuzumab (infusion) flu-like symptoms first dose bradycardia (1%) 1 0 AVB(0.5%) PML 0.5% JC+ve >2yr hair thinning (8%) flushing (34%)thyroid disease (30%) LFTs (can be late) LFTs GI upsetTTP (1.3%) site reactionsmacular oedema (0.4%) infections (HZV)hypertensionleucopenianephropathy thyroid disorders infections: LRTI HZV 1/100 pt yr accelerated washout infusion reactions capillary leak syndrome hypertensioncytotoxicinfections HZV microangiopathic haemolytic anaemia potentially teratogenic teratogenic in animals bloods 0, 1, 3, 6, 9, 12 bloods 0, 3, 6, 9, 12 2wkly testing x 6m bloods 0, 1, 3, 6, 9, 12 monthly blood/urine 48m

Sept 27 th 2011 risk management with natalizumab

PML risk estimates by index threshold in anti-JCV Ab+ patients with no prior IS use PML risk estimates for anti-JCV antibody index thresholds were calculated based on the current PML risk stratification algorithm (from September 2012) and predicted probabilities shown in the previous slide (8) for the population at or below that particular index (0.9−1.5) and for the population above an index of 1.5. For index thresholds below 0.9, patient numbers were insufficient to allow for calculation of risk estimates. Index threshold PML risk estimates (95% CI) per 1000 patients (no prior IS use) 1−24 months25−48 months49−72 months ≤ (0–0.41) 0.3 (0.04–1.13) 0.4 (0.01–2.15) ≤ (0–0.34) 0.7 (0.21–1.53) 0.7 (0.08–2.34) ≤ (0.01–0.39) 1.0 (0.48–1.98) 1.2 (0.31–2.94) ≤ (0.03–0.42) 1.2 (0.64–2.15) 1.3 (0.41–2.96) > (0.64–1.41) 8.1 (6.64–9.8) 8.5 (6.22–11.38) Plavina et al. Ann Neurol; 76:802

presentation of PML asymptomatic (MR screening) cognitive/behavioural ataxia hemiplegia

alemtuzumab NICE approval for “relapsing MS” dosing schedule: –year 1: 5d 12mg infusion –year 2: 3d 12mg infusion –subsequent years: 3d infusions if indicated

risk management strategy predose: VZV, cervical screening, HIV, HBV, HCV, TB aciclovir for first month monthly for 4 years after last infusion –CBC (platelets) –U&E and urine for microscopy –TFTs 3 monthly annual MRI (for efficacy)

long term study 87 patients median 7 year follow up ( months) 48% (41 patients) had secondary autoimmunity –3 ITP –1 neutropenia –1 haemolytic anaemia –1 Goodpasture’s (transplant required) –35 thyroid (22 Graves, 1 transient thyroiditis, 12 1 o hypothyroidism) relapses triggered reinfusion 45% –(38% 3; 4% 4; 1% 5) 60% stabilisation of improvement in disability Tuohy et al 2014 JNNP /jnnp

DMT cases in primary care

case 34-year-old woman presented for advice following a positive home pregnancy test, 7 weeks after her last menstrual period teriflunomide 14mg daily for 9 months for relapsing remitting multiple sclerosis relapse free for 5 years. relying on condoms for contraception conception was unplanned but wishes to continue with the pregnancy

options (nurses all on study day) 1.teriflunomide should be cleared by cholestyramine 2.teriflunomide should be cleared rapidly by plasmaphoresis 3.teriflunomide should be continued throughout the pregnancy 4.teriflunomide should be discontinued and allowed to clear gradually 5.termination is advisable due to an unacceptable risk of teratogenicity

pregnancy & conception interferon-  (Betaferon/Extavia Avonex Rebif) glatiramer acetate (Copaxone) natalizumab (Tysabri) fingolimod (Gilenya) teriflunomide (Aubagio) dimethyl fumarate (BG12, Tecfidera) alemtuzumab (Campath, Lemtrada) pegylated interferon (Plegridy)

case 42-year-old man 18 month review on fingolimod 0.5mg no attacks on the drug which was well tolerated felt well, had no history of infection and remained at work routine bloods

would you (neurology team on team bonding away day)? 1.admit immediately to unit equipped to manage severely immunocompromised patients 2.check JC antibody status to stratify risk of progressive multifocal leucoencephalopathy 3.continue at current dose while lymphocytes remain >0.2 x 10 9 /l 4.discontinue drug and monitor lymphocyte count to ensure recovery 5.reduce dose to alternate days and monitor lymphocyte count to ensure recovery

case 42-year-old man 18 month review on dimethyl fumarate 240mg bd no attacks on the drug which was well tolerated felt well, had no history of infection and remained at work routine bloods

would you (neurology team all abroad at conference)? 1.admit immediately to unit equipped to manage severely immunocompromised patients 2.check JC antibody status to stratify risk of progressive multifocal leucoencephalopathy 3.continue at current dose while lymphocytes remain >0.2 x 10 9 /l 4.discontinue drug and monitor lymphocyte count to ensure recovery 5.reduce dose to 120mg bd and monitor lymphocyte count to ensure recovery

case 36-year-old man with multiple sclerosis 15 months after his completing his second year of alemtuzumab (3 x 12mg infusions) clinically well with no relapses or progression. no evidence of infection, rash or bruising.

plan? 1.monitor 2.admit as emergency 3.refer back to centre

case 37-year-old woman MS presents late afternoon following an episode of transient loss of consciousness lasting about one minute. returned from two weeks abroad that morning and recommenced her medication which she had omitted while on holiday. HR 38 beats BP90/64

what’s going on?

cost effectiveness of disease modification?

UK risk-sharing scheme 6 year cohort RSS n=4137 age at eligibility (mean)38.4 age at onset (mean)30.5 female (%)75.5 disease duration (baseline) 7.7 relapses last 2 years (median [quartiles]) 3 [2-3]

time (years) EDSS UK risk-sharing scheme: modelled natural history of cohort

time (years) EDSS UK risk-sharing scheme: EDSS results against -38% target

UK risk-sharing scheme: utility results against -38% target time (years) change in utility

who is eligible? interferonsfingolimodnatalizumabteriflunomideDMFalemtuzumab first line (ABN guidelines 2009) failed interferon or copaxone 2 relapses in 1 year and active MRI (rapidly evolving severe) first line (unless rapidly evolving severe) first line (unless rapidly evolving severe) any relapsing MS step down from natalizumab (if JC +ve plus prior IS plus 2 years natalizumab treatment) either newly diagnosed or failed first line

phase III clinical trials in SPMS – cladribine – cyclophosphamide – dirucotide – dronabinol – interferon-beta1a i.m. – interferon-beta1a s/c – interferon-beta-1b s/c – intravenous immunoglobulin – lamotrigine – mitoxantrone – alemtuzumab (phase 2 only)

first choices? standard newly diagnosed –DMF –IFN/GA –teriflunomide –alemtuzumab RES newly diagnosed –natalizumab –alemtuzumab

failing first line tolerability –determine issue –switch within licensed drugs efficacy –consider concordance –escalate suboptimal response? rapidly evolving severe? DMF IFN/GA teriflunomide alemtuzumab fingolimod alemtuzumab natalizumab alemtuzumab

after second line fingolimod –concordance? –tolerability –efficacy natalizumab –efficacy (Nabs) –hypersensitivity –JC concerns alemtuzumab –efficacy –adverse event escalation: natalizumab/alemtuzumab switch: ?DMFalemtuzumab alemtuzumab fingolimod repeat course; consider ASCT ? natalizumab

treatment of acute relapse disease modification –disease modifying treatments (DMTs) management of symptoms and disability

NICE: 2014 comprehensive review and symptom check –site not specified general health social activity and participation targeted systems review

arms ADL swallow & speech bowels memory & concentration bladder ambulation spasticity sexual dysfunction mood fatigue vision numbness/tingling/pain systematic enquiry of impairment/symptoms

continence in MS 1.assessment urinary tract symptoms bowel symptoms sexual function comorbidities use of prescription and other medication and therapies 2.if the dipstick test result and person's symptoms suggest an infection, arrange a urine bacterial culture and antibiotic sensitivity test before starting antibiotic treatment treatment need not be delayed but may be adapted when results are available

continence in MS 3.be aware that bacterial colonisation will be present in people using a catheter and so urine dipstick testing and bacterial culture may be unreliable for diagnosing active infection 4.red flags for referral haematuria recurrent UTI (≥3 in 6m) loin pain recurrent catheter blockages (<6 wk of change) hydronephrosis or kidney stones on imaging (rare in MS) biochemical evidence of renal deterioration.

continence in MS 4.if catheters, appliances or pads: training access to suitable products review of products, at least every 2 years 5.offer botulinum toxin to improve bladder storage if OAB and anti-muscarinics failed or not tolerated 5.do not routinely offer antibiotic prophylaxis but consider if recent history of frequent or severe UTI

intractable constipation: what’s new prucalopride (women only, specialist centre) Peristeen (continence service)

last one: vitamin D and MS role in susceptibility secure role in disease modification unsure advice on high dose replacement

thank you reflections or questions?